DRY AMD MODELS

Reproducible dry Age-Related Macular Degeneration Models.

Age-Related Macular Degeneration (AMD) has a global prevalence of around 170 million. Dry AMD separates itself from wet AMD by lacking any vascular involvement in its pathological course. 85 to 90% of AMD cases are dry; they cannot be treated, and might develop into wet AMD which is the more severe, but treatable, form.

Data from the WHO shows that AMD has been holding a spot in the world’s top 7 causes of blindness and visual impairment for years now. This has to change. With your critical pipelines and our models at PharmaLegacy, AMD might one day lose its spot on the world’s leading causes of visual impairment and blindness.

Dry AMD

MODELS / SERVICES

Pioneering Healthcare Solutions:

  • Operations and IT structured for maximum protection of clients’ data and IP
  • Scientific staff with an average of over 15 years of experience in pharmacology
  • AAALAC accredited vivarium
  • Capacity to run 200+ concurrent animal studies

Looking for data-driven insights for your macular degeneration studies? Talk to PharmaLegacy

Contact Us

We’re ready when you are.

Tell us your pharmacology challenges.